• Vaccitech to Present at Upcoming November Investors Conferences

    المصدر: Nasdaq GlobeNewswire / 09 نوفمبر 2022 08:00:01   America/New_York

    OXFORD, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines for the treatment and prevention of infectious diseases, cancer, and autoimmune diseases, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Gemma Brown will be presenting at the following investment conferences in November.

    Event:Jefferies London Healthcare Conference
    Date:Tuesday, November 15 – Thursday, November 17
    Presentation:Fireside Chat
    Time:17:35 p.m. GMT on Tuesday, November 15
     
    Event:Piper Sandler 34th Annual Healthcare Conference
    Date:Tuesday, November 29 – Thursday, December 01
    Presentation:Company Overview
    Time:09:50 a.m. EST on Thursday, December 01

    Vaccitech will also participate in 1x1 investor meetings at the conferences. Meetings can be booked directly with the Company or with the relevant bank representatives.

    About Vaccitech plc
    Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer, autoimmunity and diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified Vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestones and royalty income received by OUI from AstraZeneca.

    For further information about Vaccitech, please visit: https://vaccitech.co.uk/   

    IR contacts:
    Christopher M. Calabrese 
    Managing Director 
    LifeSci Advisors
    917-680-5608
    ccalabrese@lifesciadvisors.com 

    Kevin Gardner
    Managing Director
    LifeSci Advisors
    617-283-2856
    kgardner@lifesciadvisors.com
      
    Media contact:
    Mike Beyer
    SAM BROWN, INC
    312-961-2502
    mikebeyer@sambrown.com
     
      
    Company contact:
    Jonothan Blackbourn
    IR & PR Manager
    Vaccitech
    IR@vaccitech.co.uk
     


    Primary Logo

شارك على،